Bacteriophages - Papers by Dr. Soothill and by Biocontrol staff

Alkawash MA, Soothill JS, Schiller NL (2006).
Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms.
Acta Pathologica, Microbiologica et Immunologica Scandinavica 114: 131-138.

Barrow PA & Soothill JS (1997).
Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of the potential.
Trends Microbiol 5: 268-271.

Harper DR, Kutter E (2008).
Biological control by micro-organisms.
In "The Encyclopedia of Life Sciences", John Wiley & Sons, Chichester; on line

Harper DR (2006).
Biological control by micro-organisms.
In "The Encyclopedia of Life Sciences", John Wiley & Sons, Chichester; on line

Marza JA, Soothill JS, Boydell P, Collyns TA (2006).
Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients.
Burns 32: 644-646.

Soothill JS (1992).
Treatment of experimental infections of mice with bacteriophages.
J Med Microbiology. 37: 258-261.

Soothill JS, Hawkins C, Anggard EA, Harper DR (2004).
Therapeutic use of bacteriophages.
Lancet Infectious Diseases 4: 544-545.

Soothill JS (1994).
Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa.
Burns. 20: 209-211.

Barrow PA and Soothill JS (1997).
Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of the potential.
Trends Microbiol 5: 268-271.

Bradbury J (2004).
My enemy's enemy is my friend.
The Lancet 363: 624-625

Bruttin A and Brüssow H (2005).
Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy.
Antimicrob Agents Chemother. 49:2874-2878.

Clark JR and March JB (2006).
Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials.
Trends Biotechnol. 24: 212-218.

Dixon B (2004).
New dawn for phage therapy.
The Lancet Infectious Diseases 4: 186.

Eaton, Monroe D. and Stanhope Bayne-Jones (1934).
Bacteriophage Therapy.
JAMA 103:1769-1776; 1847-1853; 1934-1939.

Hausler T (2006).
Viruses vs. Superbugs: A Solution to the Antibiotics Crisis?
MacMillan, New York.

Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H and Imai SJ (2005). Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases.
Infect Chemother 11: 211-219.

MacGregor J (2003).
Set a bug to catch a bug.
New Scientist 178: 36-43.

Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S (1996):
Long-circulating bacteriophages as antibacterial agents.
PNAS USA 93: 3188-3192.

Pirisi A (2000).
Phage Therapy, advantages over antibiotics?
The Lancet 356: 1418.

Schoolnik GK, Summers WC, Watson JD (2004).
Phage offer a real alternative.
Nature Biotechnology 22: 167-168.

Slopek, Stefan, Beata Weber-Dabrowska, Marek Dabrowski and Alina Kucharewica-Krukowska, (1987).
Results of Bacteriophage Treatment of Suppurative Bacterial Infections in the Years 1981-1986.
Arch. Immunol. Ther. Exp. 35:569-583.

Smith, H. W. and R. B. Huggins (1982).
Successful treatment of experimental E. coli Infections in mice using Phage: its general superiority over Antibiotics.
J. Gen. Microbiology 128:307-318.

Smith, H. W. and R. B. Huggins (1983) br> Effectiveness of Phages in treating Experimental E. coli Diarrhoea in calves, piglets and lambs.
J. Gen. Microbiology 129:2659-2675.

Smith, H. W. and R. B. Huggins. (1987)
The Control of Experimental E. coli diarrhea in calves by means of Bacteriophage.
J. Gen. Microbiology 133:1111-1126

Soothill JS. (1992).
Treatment of experimental infections of mice with bacteriophages.
J Med Microbiology. 37: 258-261.

Smith, H. W., R. B. Huggins and K. M. Shaw. (1987)
Factors influencing the Survival and Multiplication of Bacteriophages in Calves and in their Environment.
J. Gen. Microbiology 133:1127-1135.

Soothill JS. (1992).
Use of bacteriophage in the treatment of infections.
M.D. Thesis. University of London.

Soothill JS. (1994).
Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa.
Burns. 20: 209-211.

Soothill JS, Hawkins C, Anggard EA & Harper DR (2004).
Therapeutic use of bacteriophages.
Lancet Infectious Diseases 4: 544-545.

Thiel K (2004).
Old dogma, new tricks; 21st century phage therapy.
Nature Biotechnology 22: 31-36.

Carmeli Y, Troillet N, Eliopoulos GM, Samore MH (1999).
Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother. 43:1379-1382.

Carmeli Y, Troillet N, Karchmer AW, Samore MH (2003).
Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa.
Arch Intern Med. 159:1127-1132.

Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL (2003).
Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995-2000.
Diagnostic Microbiology and Infectious Disease 45:245-50.

Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R (2001).
Characterization of Pseudomonas aeruginosa Isolates: Occurrence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999.
Clinical Infectious Diseases 32(Suppl 2):S146-55.

Henwood CJ, Livermore DM, James D, Warner M; Pseudomonas Study Group. (2001).
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test..
J Antimicrob Chemother. 47: 789-799.

Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF (2003).
Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.
Antimicrob Agents Chemother.47:1681-1688.

Livermore DM, Woodford N. (2000).
Carbapenemases: a problem in waiting?
Current Opinions in Microbiology 3:489-495.

Mah T-F, Pitts B, Pellock B, Walker GC, Stewart PS & O'Toole GA (2003).
A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance.
Nature 426; 306-310.

Mokaddas EM, Sanyal SC (1999).
Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam.
J Chemother. 11:93-96.

Navon-Venezia S, Ben-Ami R, Carmeli Y (2005).
Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting.
Curr Opin Infect Dis. 2005 18: 306-313.

Pitt TL, Sparrow M, Warner M, Stefanidou M (2003).
Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.
Thorax 58:794-796.

Plotkowski M-C, Tournier J-M, Puchelle E (1996).
Pseudomonas aeruginosa strains possess specific adhesins for laminin.
Infection And Immunity, 64, 600-605.

Thomson JM, Bonomo RA (2005).
The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!
Curr Opin Microbiol. 2005 8: 518-524.

Van Eldere J (2003).
Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.
J Antimicrob Chemother. 51:347-352.

Woodford N, Palepou MF, Babini GS, Bates J, Livermore DM (1998).
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Lancet 352: 546-547.

Wroblewska M (2006).
Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. infections: the state of the art.
Arch Immunol Ther Exp (Warsz) 54: 113-120.

Chen S, Burns JA, Rudoy R (2006). Pseudomonas infection.

Qarah S, Cunha BA, Dua P, Lessnau K-D (2005). Pseudomonas aeruginosa infections

Todar K (2004). Todar's Online Textbook of Bacteriology: Pseudomonas aeruginosa.

Biocontrol Limited UK	Biocontrol International Inc. USA
Company Reg No. 3452169	Delaware Reg No. 4665692